Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target

Reuters12-05

Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target

Emerging Growth Research has released a flash report on OSR Holdings Inc. $(OSRH)$, reaffirming its Buy-Emerging rating and setting a 12-month price target of $10.00, representing a potential 1,487% upside from the company's recent closing price. The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at $815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01. The agreement, which includes an expected $20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276983) on December 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589783230?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589783230","market":"nz","top_or_hot":-1,"title":"Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Emerging Growth Research has released a flash report on OSR Holdings Inc. <a href=\"https://laohu8.com/S/OSRH\">$(OSRH)$</a>, reaffirming its Buy-Emerging rating and setting a 12-month price target of $10.00, representing a potential 1,487% upside from the company's recent closing price. The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at $815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01. The agreement, which includes an expected $20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276983) on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-05 04:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Emerging Growth Research has released a flash report on OSR Holdings Inc. <a href=\"https://laohu8.com/S/OSRH\">$(OSRH)$</a>, reaffirming its Buy-Emerging rating and setting a 12-month price target of $10.00, representing a potential 1,487% upside from the company's recent closing price. The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at $815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01. The agreement, which includes an expected $20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276983) on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4SmJC2:1","article_id":"2589783230","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589783230","pubTimestamp":1764879594,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Emerging Growth Research has released a flash report on OSR Holdings Inc. , reaffirming its Buy-Emerging rating and setting a 12-month price target of $10.00, representing a potential 1,487% upside from the company's recent closing price. The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at $815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01. The agreement, which includes an expected $20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OSRH":"OSR Holdings"},"translate_title":"Emerging Growth Research重申买入OSR Holdings，目标价10美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSRH":0.9},"content_text":"Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target\n    \n\n        Emerging Growth Research has released a flash report on OSR Holdings Inc. $(OSRH)$, reaffirming its Buy-Emerging rating and setting a 12-month price target of $10.00, representing a potential 1,487% upside from the company's recent closing price. The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at $815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01. The agreement, which includes an expected $20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276983) on December 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589783230","isCrawlerRequest":true}